Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review

被引：48

作者：

Assi, Tarek ^{[1
]}

Kattan, Joseph ^{[1
]}

Rassy, Elie ^{[1
,2
]}

Nassereddine, Hussein ^{[1
]}

Farhat, Fadi ^{[1
]}

Honore, Charles ^{[2
]}

Le Cesne, Axel ^{[2
]}

Adam, Julien ^{[2
]}

Mir, Olivier ^{[2
]}

机构：

[1] St Joseph Univ, Dept Hematol Oncol, Fac Med, Beirut, Lebanon

[2] French Sarcoma Grp, Gustave Roussy Canc Campus, Villejuif, France

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2020年 / 153卷

关键词：

Liposarcoma; Soft tissue sarcoma; CDK4; MDM2; Palbociclib; Abemaciclib; Ribociclib; SOFT-TISSUE SARCOMA; PHASE-II; 1ST-LINE TREATMENT; SYNOVIAL SARCOMA; INHIBITOR; CANCER; DOXORUBICIN; ABEMACICLIB; PALBOCICLIB; EFFICACY;

D O I：

10.1016/j.critrevonc.2020.103029

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Well-differentiated/dedifferentiated (WD/DD) liposarcomas, the most common form of liposarcomas, constitute up to 20 % of all soft tissue sarcomas. Several oncogenes are thought to be involved in liposarcoma pathogenesis, mainly MDM2, CDK4 and HMGA2. While MDM2 inhibitors are now tested in clinical trials, a second actionable and promising target appears to be cyclin-dependent kinase 4 (CDK4), which is amplified in up to 90 % of well differentiated or dedifferentiated (WD/DD) liposarcoma. With the paucity of available therapeutic options, the inhibition of CDK4 represent a potential therapeutic option. In this paper, we review the role of CDK4/6 inhibitors in targeting the commonly identified CDK4 amplification in WD/DD liposarcoma, with an emphasis on the published and currently ongoing trials.

引用

页数：6

共 50 条

[41] Cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced oestrogen receptor-positive breast cancer
Dubianski, Roman
Jagiello-Gruszfeld, Agnieszka
Nowecki, Zbigniew
ONCOLOGY IN CLINICAL PRACTICE, 2016, 12 (06): : 209 - 214
[42] Review of Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer
Hecht, Keith A.
Selby, Christopher
ANNALS OF PHARMACOTHERAPY, 2019, 53 (02) : 195 - 203
[43] A comprehensive bioinformatic analysis of cyclin-dependent kinase 2 (CDK2) in glioma
Liu, Hengrui
Weng, Jieling
GENE, 2022, 822
[44] Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma
Ma, Hangzhan
Seebacher, Nicole A.
Hornicek, Francis J.
Duan, Zhenfeng
EBIOMEDICINE, 2019, 39 : 182 - 193
[45] Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment
Susanti, Ni Made Pitri
Tjahjono, Daryono Hadi
MOLECULES, 2021, 26 (15):
[46] Cyclin-Dependent Kinase 4 and 6 Inhibitors as Breast Cancer Therapy: Research Progress and Prospects
Li, Xiandeng
PHARMACEUTICAL CHEMISTRY JOURNAL, 2022, 56 (01) : 71 - 77
[47] Cyclin-Dependent Kinase 4 and 6 Inhibitors as Breast Cancer Therapy: Research Progress and Prospects
Xiandeng Li
Pharmaceutical Chemistry Journal, 2022, 56 : 71 - 77
[48] Abemaciclib, a potent cyclin-dependent kinase 4 and 6 inhibitor, for treatment of ER-positive metastatic breast cancer
Lee, Karla A.
Shepherd, Scott T. C.
Johnston, Stephen R. D.
FUTURE ONCOLOGY, 2019, 15 (29) : 3309 - 3326
[49] Thromboembolism profiles associated with cyclin-dependent kinase 4/6 inhibitors: a real-world pharmacovigilance study and a systematic review
Gao, Siyuan
Li, Yu
He, Zhichao
Zhu, Jianhong
Liang, Dan
Yang, Shan
Mo, Jiayao
Lam, Kakei
Yu, Xiaoxia
Huang, Ming
Wu, Junyan
EXPERT OPINION ON DRUG SAFETY, 2023, 22 (07) : 599 - 609
[50] Emerging Skin Toxicities in Patients with Breast Cancer Treated with New Cyclin-Dependent Kinase 4/6 Inhibitors: A Systematic Review
Silvestri, Martina
Cristaudo, Antonio
Morrone, Aldo
Messina, Claudia
Bennardo, Luigi
Nistico, Steven Paul
Mariano, Maria
Cameli, Norma
DRUG SAFETY, 2021, 44 (07) : 725 - 732

← 1 2 3 4 5 →